Citations

Mayo Clinic

Showing 10 of 108572 citations.

Fusion Modeling: Combining Clinical and Imaging Data to Advance Cardiac Care
Assen, Marly van , Tariq, Amara , Razavi, Alexander C. , Yang, Carl , Banerjee, Imon , Cecco, Carlo N. De , van Assen, Marly , De Cecco, Carlo N , Banerjee, Imon

Circulation: Cardiovascular Imaging | December 11, 2023 | Volume: 16 | Issue: 12 | Pages: No page available

10.1161/circimaging.122.014533 | PMID 38073535 Get It

In addition to the traditional clinical risk factors, an increasing amount of imaging biomarkers have shown value for cardiovascular risk prediction. Clinical and imaging data are captured from a variety of data sources during multiple patient encounters and are often analyzed independently. Initial studies showed that fusion of both clinical and imaging features results in superior prognostic performance compared with traditional scores. There are different approaches to fusion modeling, combining multiple data resources to optimize predictions, each with its own advantages and disadvantages. However, manual extraction of clinical and imaging data is time and labor intensive and often not feasible in clinical practice. An automated approach for clinical and imaging data extraction is highly desirable. Convolutional neural networks and natural language processing can be utilized for the extraction of electronic medical record data, imaging studies, and free-text data. This review outlines the current status of cardiovascular risk prediction and fusion modeling; and in addition gives an overview of different artificial intelligence approaches to automatically extract data from images and electronic medical records for this purpose.
Identification of the novel HLA‐B*57:168 allele by next generation sequencing
Du, Zeying , Santiago, Rodrigo Silveira de , Ussery, Totiana A., Elrefaei, Mohamed , Williams, Charles, Santiago, Rodrigo, Ussery, Totiana, Elrefaei, Mohamed , Du, Zeying , Williams, Charles, Santiago, Rodrigo

HLA | December 11, 2023 | Volume: 103 | Issue: 1 | Pages: No page available

10.1111/tan.15327 | PMID 38073446 Get It

HLA‐B*57:168 differs from HLA‐B*57:01:01:01 by one nucleotide substitution at codon 325 (TGC > TCC) in exon 7.
Irritable bowel syndrome – less irritable, or better treatments?
Travers, Paul , Lacy, Brian E. , Cangemi, David J. , Travers, Paul

Current Opinion in Gastroenterology | December 11, 2023 | Volume: 40 | Issue: 1 | Pages: 27-33

10.1097/mog.0000000000000987 | PMID 38078610 Get It

Purpose of review Irritable bowel syndrome (IBS) is a chronic, often bothersome disorder of gut-brain interaction (DGBI) characterized by abdominal pain associated with a change in stool frequency and/or caliber. Recent advancements have improved our understanding of the underlying pathophysiology, thus opening new avenues for therapeutic intervention. The purpose of this review is to summarize the current literature regarding treatment modalities for IBS. Recent findings Altering the gut microbiome via probiotic and antibiotic administration, avoiding dietary triggers, and modulating the gut-brain axis have all proven efficacious for the management of IBS symptoms. Several gut-specific pharmacotherapies are approved for the treatment of IBS, many of which primarily address either diarrhea or constipation, although many patients remain symptomatic despite appropriate use. Brain-gut behavioral therapies (BGBTs) are increasingly used to treat symptoms of IBS, particularly in those who do not respond to traditional therapies. Virtual reality represents an exciting new approach to treating DGBIs, like IBS, though data are limited. Summary As our understanding of IBS continues to evolve, so should our therapeutic approach. Individualizing the therapeutic approach is of utmost importance.
Decreased Plasma Levels of Kynurenine and Kynurenic Acid in Previously Treated and First-Episode Antipsychotic-Naive Schizophrenia Patients
Petronijević, Nataša , Stašević, Milena, Karličić, Ivana Stašević, Velimirović, Milica , Stojković, T. , Ristić, Slavica , Stojković, Mina , Nikolić, Tatjana , Petronijević, Nataša , Ristić, Slavica , Stojković, Mina , Nikolić, Tatjana , Marković, Miloš , Milić, Nataša

Cells | December 11, 2023 | Volume: 12 | Issue: 24 | Pages: 2814

10.3390/cells12242814 | PMID 38132134 Get It

Tryptophan (TRP) catabolites exert neuroactive effects, with the plethora of evidence suggesting that kynurenic acid (KYNA), a catabolite of the kynurenine pathway (KP), acts as the regulator of glutamate and acetylcholine in the brain, contributing to the schizophrenia pathophysiology. Newer evidence regarding measures of KP metabolites in the blood of schizophrenia patients and from the central nervous system suggest that blood levels of these metabolites by no means could reflect pathological changes of TRP degradation in the brain. The aim of this study was to investigate plasma concentrations of TRP, kynurenine (KYN) and KYNA at the acute phase and remission of schizophrenia in a prospective, case-control study of highly selected and matched schizophrenia patients and healthy individuals. Our study revealed significantly decreased KYN and KYNA in schizophrenia patients (p < 0.001), irrespective of illness state, type of antipsychotic treatment, number of episodes or illness duration and no differences in the KYN/TRP ratio between schizophrenia patients and healthy individuals. These findings could be interpreted as indices that kynurenine pathway might not be dysregulated in the periphery and that other factors contribute to observed disturbances in concentrations, but as our study had certain limitations, we cannot draw definite conclusions. Further studies, especially those exploring other body compartments that participate in kynurenine pathway, are needed.
Evaluating the Association Between Sociodemographic and Health Variables With Baseline Concussion Testing in Young Athletes
Kreitner, Liga , Crowley, Eric M., Weaver, Amy L. , Soma, David , Crowley, Eric, Kreitner, Liga A , Wi, Chung‐Il

Orthopaedic Journal of Sports Medicine | December 11, 2023 | Volume: 11 | Issue: 12 | Pages: No page available

10.1177/23259671231214222 | PMID 38090656 Get It

Background: Baseline concussion testing can be helpful to perform when providing concussion care for young athletes. To appropriately interpret these data, it is important to understand how certain factors may affect concussion testing. Purpose: To examine the relationship of sociodemographic and health variables with baseline concussion testing in young athletes. Study Design: Cross-sectional study; Level of evidence, 3. Methods: High school and middle school athletes competing in sports or positions at high risk for concussion (football, soccer, ice hockey, wrestling, lacrosse, and pitchers/catchers in baseball/softball) during the 2020-2021 or 2021-2022 academic years completed annual baseline concussion testing and were included in the study. Baseline data included self-reported demographic and medical information, a graded symptom checklist, the Standardized Assessment of Concussion, and the King-Devick test. A validated measure, HOUSES (HOUsing-based index of SocioEconomic Status), was used to determine participants’ socioeconomic status (SES) by linking personal address information to publicly available property data. Multivariable linear regression models were fit to analyze the relationship of concussion baseline testing to sociodemographic and health variables. Results: Among the eligible 2747 athletes (mean age, 15.4 ± 1.5 years; 73.6% male), the mean Standardized Assessment of Concussion score was 26.7 ± 2.0 and the mean best King-Devick test time was 50.3 ± 10.1 seconds. Higher baseline symptom severity scores were related to lower SES ( P = .002). A lower (ie, poorer) mean Standardized Assessment of Concussion score was significantly associated with the following in the multivariable model: male sex ( P < .001), younger age ( P < .001), Black/African American race ( P = .029), Hispanic ethnicity ( P = .016), previous diagnosis of learning disorder or attention-deficit hyperactivity disorder ( P < .001), and lower SES ( P = .003). A higher (ie, poorer) mean King-Devick test time was related to younger age, previous diagnosis of a learning disorder or attention-deficit hyperactivity disorder, and lower SES (all P < .001). Conclusion: Baseline concussion testing was found to be associated with certain sociodemographic variables and underlying health conditions in high school and middle school athletes.
Most patients with disorders of gut‐brain interaction receive pharmacotherapy with major or moderate drug‐gene interactions
Varma, Revati , Matey, Eric T. , Wright, Jessica , Deb, Brototo , Szarka, Lawrence A., Bailey, Kent R. , Bharucha, Adil E. , Bharucha, A E , Wright, Jessica A , Staab, Jeffrey P. , Lazaridis, Konstantinos N.

Neurogastroenterology & Motility | December 11, 2023 | Volume: 36 | Issue: 2 | Pages: No page available

10.1111/nmo.14722 | PMID 38072827 Get It

AbstractBackgroundHow variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut‐ brain interaction is unclear.AimsTo assess the prevalence of pharmacogenomics‐predicted drug‐gene interactions and symptom outcomes for patients with disorders of gut‐brain interaction.MethodsPatients who were treated in our clinical practice for functional dyspepsia/bowel disorder underwent pharmacogenomic testing. The change in symptoms from baseline to 6 months was compared for patients with variations in CYP2D6 and CYP2C19, which metabolize neuromodulators, and SLC6A4, which encodes the sodium‐ dependent serotonin transporter.ResultsAt baseline, 79 of 94 participants (84%) had at least one predicted major drug‐ gene interaction, and all 94 (100%) had at least one predicted moderate interaction. For the 44 participants who completed a survey of their symptoms at 6 months, the mean (SD) irritable bowel syndrome‐symptom severity score decreased from 284 (71) at baseline to 231 (95) at 6 months (p < 0.001). Among patients taking selective serotonin reuptake inhibitors, the decrease in symptom severity (p = 0.03) and pain (p = 0.002) scores from baseline to 6 months was greater for patients with a homozygous SLC6A4 long/long genotype (n = 30) (ie, increased serotonin transporter activity) than for patients with homozygous short/short or heterozygous long/short genotypes (n = 64). Symptom outcomes were not affected by CYP2D6 or CYP2C19 variations.ConclusionsThe homozygous SLC6A4 long/long genotype confers better symptom resolution for patients with disorders of gut‐brain interaction who take selective serotonin reuptake inhibitors than do the homozygous short/short or heterozygous long/short genotypes.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Gangat, Naseema , Karrar, Omer , Iftikhar, Moazah, McCullough, Kristen , Johnson, Isla McKerrow , Abdelmagid, Maymona, Abdallah, Mostafa, Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne , Sproat, Lisa, Khera, Nandita , Yi, Cecilia Y. Arana , Tefferi, Ayalew , Saliba, Antoine N. , Johnson, Isla M, Begna, Kebede , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Litzow, Mark R. , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Badar, Talha , Murthy, Hemant S , Arana Yi, Cecilia Y , Tefferi, Ayalew , McCullough, Kristen B , Saliba, Antoine N , Alkhateeb, Hassan B. , Hefazi, Mehrdad , Hogan, William J. , Shah, Meera , Murthy, Hemant S. , Yi, Cecilia Arana

American Journal of Hematology | December 10, 2023 | Volume: 99 | Issue: 2 | Pages: 193-202

10.1002/ajh.27138 | PMID 38071734 Get It

Abstract Venetoclax + hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND‐AML was to identify molecular predictors of treatment response to Ven‐HMA and survival; European LeukemiaNet (ELN) genetic risk assignment was favorable 15%, intermediate 16%, and adverse 69%. Complete remission, with (CR) or without (CRi), count recovery, was documented in 182 (60%) patients. In multivariable analysis, inclusive of mutations only, “favorable” predictors of CR/CRi were NPM1 (86% vs. 56%), IDH2 (80% vs. 58%), and DDX41 (100% vs. 58%) and “unfavorable” TP53 (40% vs. 67%), FLT3‐ ITD (36% vs. 63%), and RUNX1 (44% vs. 64%) mutations; significance was sustained for each mutation after adjustment for age, karyotype, and therapy‐related qualification. CR/CRi rates ranged from 36%, in the presence of unfavorable and absence of favorable mutation, to 91%, in the presence of favorable and absence of unfavorable mutation. At median follow‐up of 8.5 months, 174 deaths and 41 allogeneic stem cell transplants (ASCT) were recorded. In multivariable analysis, risk factors for inferior survival included failure to achieve CR/CRi (HR 3.4, 95% CI 2.5–4.8), adverse karyotype (1.6, 1.1–2.6), TP53 mutation (1.6, 1.0–2.4), and absence of IDH2 mutation (2.2, 1.0–4.7); these risk factors were subsequently applied to construct an HR‐weighted risk model that performed better than the ELN genetic risk model (AIC 1661 vs. 1750): low ( n = 130; median survival 28.9 months), intermediate ( n = 105; median 9.6 months), and high ( n = 66; median 3.1 months; p < .001); survival in each risk category was significantly upgraded by ASCT. The current study identifies genotype signatures for predicting response and proposes a 3‐tiered, CR/CRi‐based, and genetics‐enhanced survival model for AML patients receiving upfront therapy with Ven‐HMA.
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?
Lepage-Ratte, Melissa Fay , Hibbert, Benjamin , Mathew, Rebecca , Hibbert, Benjamin

European Heart Journal - Cardiovascular Pharmacotherapy | December 10, 2023 | Volume: 10 | Issue: 2 | Pages: 98-99

10.1093/ehjcvp/pvad098 | PMID 38081223 Get It

Acute postoperative and rehabilitation care managed in a virtual hybrid hospital‐at‐home after a total knee arthroplasty: A case report
Maita, Karla C. , Brand, Rusty C., Seep, Phillip J., Maniaci, Michael J. , Torres-Guzman, Ricardo A, Maniaci, Michael J , Paulson, Margaret R. , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Forte, Antonio J.

Clinical Case Reports | December 9, 2023 | Volume: 11 | Issue: 12 | Pages: No page available

10.1002/ccr3.8318 | PMID 38084352 Get It

Key Clinical Messages This case report demonstrates a virtual hybrid hospital‐at‐home program can provide inpatient‐level postoperative and rehabilitative care after total knee arthroplasty to a medically complex patient in the comfort of their own home. Abstract Advanced Care at Home combines virtual providers with in‐home care delivery. We report a case of virtual postoperative and rehabilitative care in a medically complex patient who underwent a total knee arthroplasty. This new model of care delivery allows effective patient‐provider communication and meets patient needs in the postoperative period.
Mid-term outcomes of three commonly used surgical reconstructions for scapholunate instability
Kampen, Robert J. van , Coert, J. Henk , Moran, Steven L. , van Kampen, Robert J

Journal of Hand Surgery (European Volume) | December 9, 2023 | Volume: 49 | Issue: 7 | Pages: 852-858

10.1177/17531934231219191 | PMID 38069863 Get It

This retrospective analysis reports the mid-term (>2 years) outcomes of capsulodesis, (modified) Brunelli tenodesis and bone-ligament-bone reconstruction for scapholunate ligament instability. In total, 60 patients (64 wrists) returned the Patient-Rated Wrist Evaluation and Disabilities of the Arm, Shoulder, and Hand questionnaires. Of these participants, 42 (46 wrists) returned for a wrist examination and radiographs. In the questionnaire group, the mean follow-up for capsulodesis was 11.8 years, tenodesis 5.9 years and bone-ligament-bone 8.9 years. In the objective outcomes group, the mean follow-up was 10.2 years for capsulodesis, 5.7 for tenodesis and 8.9 for bone-ligament-bone. In all groups, some patients showed radiographic deterioration, which did not always correlate with poor functional outcome. With a mean follow-up greater than 5 years, there was no substantial difference in clinical outcomes and patient-based outcome questionnaires between capsulodesis, tenodesis or bone-ligament-bone reconstruction for the treatment of scapholunate instability. This study emphasizes the need for further research. Surgeons should use the technique that produces the fewest complications. Level of evidence III